Apolipoprotein A1
Apolipoproteins are the protein constituents of the lipoproteins that are the transporters of cholesterol and other important molecules. Apolipoproteins are produced in the liver and intestine and their production is controlled by diet, hormones (insulin, glucagon and androgens), alcohol intake and various drugs such as statins. There are at least nine types of apolipoproteins including apo A-1, apo B, and apo E. Apo A-1 is a primary protein associated with HDL particles and it is a cofactor for lecithin cholesterol-acyltransferase (LCAT) responsible for the formation of most plasma cholesteryl esters. The major role of Apo A-1 is reverse cholesterol transport and the removal of excess cholesterol from tissues. Decreased production or deficiency of Apo A-1 is associated with HDL deficiencies, including Tangier disease (familial alpha-lipoproteinemia deficiency) and with systemic non-neuropathic amyloidosis. Low levels of Apo A-1 are associated with the increased risk of coronary artery disease (CAD). Lower levels are also seen in nephrosis and renal failure, uncontrolled diabetes and liver disease.
The best assessment of lipoprotein disorders is by evaluating apolipoprotein ratio. The Apolipoprotein assessment panel consists of measuring Apolipoprotein A1 and Apolipoprotein B (major protein component of Low Density Lipoprotein-LDL). The ratio is used for assessment of the risk for Coronary Heart Disease (CHD and peripheral vascular diseases. Many individuals with CHD have been found to have normal serum lipids and cholesterol levels while the levels of the apolipoproteins might be elevated. The combined determination of apolipoprotein A-1/apolipoprotein B, and the calculation of the apolipoprotein B: apolipoprotein A-1 ratio can reflect a lipid metabolism disorder and the risk of developing atherosclerosis or coronary heart disease, thus providing an excellent addition to the classical HDL/LDL-cholesterol determination. A high level of apolipoprotein A-1 (HDL) and a low level of apolipoprotein B (LDL) correlate best with a low risk for these diseases. However, in patients without a history of CHD, the US Preventive Services Task Force (USPSTF) does not recommend lipoprotein assessment as part of a general coronary risk assessment.
- To evaluate the risk of atherosclerotic cardiovascular disease
- As an aid in diagnosis of Familial α-lipoprotein deficiency (Tangier Disease)
- As an aid in diagnosis of LCAT deficiency
Increased in:
- Familial hyperalphalipoproteinemia
- Familial cholesteryl ester transfer protein (CEPT) deficiency
- Hormone therapy
- Alcohol consumption
Decreased in:
- Familia hypoalphalipoproteinemia
- Apo A-I variants (e.g., Apo A-1 Milano)
- Fish eye disease
- Familial lecithin-cholesterol acyltranferase (LCAT) deficiency
- Tangier disease
- Familia Apo A-I deficiency (with or without apo CIII/Apo A-IV deficiency)
- Hepatocellular disorders
- Cholestasis
- Nephrotic syndrome
- Chronic renal disease
- Malignancy
- Statin treatment
Male: 99-178 mg/dL Female: 101-199 mg/dL
Serum (SST), Plasma.
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: 30 days
- QJM. 2006 May;99(5):277-87. [PMID: 16504986]
- N Engl J Med. 1983, 309(7):385-9. [PMID: 6410239]
- Biochimie. 2014 Jan;96:56-66. [PMID: 24012775]
- J Intern Med. 2004 Feb;255(2):188-205. [PMID: 14746556]
- Arch Med Res. 2015 Jul;46(5):351-60. [PMID: 26048453]
- Alan H. B Wu. Tietz Clinical Guide to Laboratory Tests. Fourth edition 2006. Page 142-4